Pluri (PLUR) Total Non-Current Liabilities (2011 - 2025)
Pluri (PLUR) reported Total Non-Current Liabilities of $7.5 million for Q4 2025, down 74.56% year-over-year from $29.3 million in Q4 2024, and up 4.25% quarter-over-quarter from $7.2 million in Q3 2025.
Pluri (PLUR) Total Non-Current Liabilities (2011 - 2025) Analysis & Trends
Pluri (PLUR) has 15 years of Total Non-Current Liabilities data on file, last reported at $7.5 million in Q4 2025.
- Total Non-Current Liabilities for Q4 2025 came in at $7.5 million, down 74.56% year-over-year; the trailing twelve-month figure through Dec 2025 was $7.5 million (down 74.56% YoY), and the FY2025 annual result was $7.2 million, down 75.66% from the prior year.
- Total Non-Current Liabilities rose to $7.5 million in Q4 2025 per PLUR's latest filing, from $7.2 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $31.7 million in Q4 2021 and troughed at $1.1 million in Q1 2021.
- A 5-year average of $24.6 million and a median of $29.5 million in 2024 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2021 and 2025: Total Non-Current Liabilities surged 2737.27% in 2021, then slumped 76.85% in 2025.
- A 5-year view of Total Non-Current Liabilities shows it stood at $31.7 million in 2021, then dropped by 6.53% to $29.7 million in 2022, then gained by 2.49% to $30.4 million in 2023, then dropped by 3.55% to $29.3 million in 2024, then sank by 74.56% to $7.5 million in 2025.
- Business Quant data shows PLUR's Total Non-Current Liabilities at $7.5 million in Q4 2025, $7.2 million in Q3 2025, and $7.2 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 42,980.09 |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 64.76 Mn |
| 10 | Pluri | 21.39 Mn | 21.87 Mn | 86,000.00 | 7.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.46 Mn |
| Sep 30, 2025 | 7.16 Mn |
| Jun 30, 2025 | 7.22 Mn |
| Mar 31, 2025 | 31.22 Mn |
| Dec 31, 2024 | 29.34 Mn |
| Sep 30, 2024 | 30.92 Mn |
| Jun 30, 2024 | 29.66 Mn |
| Mar 31, 2024 | 30.02 Mn |
| Dec 31, 2023 | 30.42 Mn |
| Sep 30, 2023 | 29.18 Mn |
| Jun 30, 2023 | 29.88 Mn |
| Mar 31, 2023 | 29.98 Mn |
| Dec 31, 2022 | 29.68 Mn |
| Sep 30, 2022 | 27.84 Mn |
| Jun 30, 2022 | 29.05 Mn |
| Mar 31, 2022 | 31.16 Mn |
| Dec 31, 2021 | 31.75 Mn |
| Sep 30, 2021 | 24.48 Mn |
| Jun 30, 2021 | 24.87 Mn |
| Mar 31, 2021 | 1.12 Mn |